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Summary: Pharmacokinetics is a field that has matured over the 
last 40 years, and we now have a detailed pharmacologic and physi-
ological understanding of “what the body does to a drug.” The sub-
ject has reached a point whereby reasonably accurate prediction of 
human pharmacokinetic behavior of a chemical, based on its physico-
chemical properties and some in vitro experimentation, is possible. 
Pharmacodynamics as a discipline is even older than pharmacokinet-
ics, but we are not in such a strong position in terms of prediction 
of human pharmacodynamics, as we are with pharmacokinetics. 
However, pharmacokinetic/pharmacodynamic (PKPD) modeling is 
making rapid strides. PKPD is very much a quantitative discipline 
in the sense that theory can be translated into temporal profiles of 
concentration or response, even to the extent of being able to design 
dosage regimens for individual patients. The hub of this quantita-
tive discipline is a PKPD model, and PKPD modeling has become an 
essential activity in preclinical and clinical drug development and 
clinical drug usage.
Recently, the European Medicines Agency (EMA) and the 
European Association of Pharmaceutical Industries and Associates 
(EFPIA) brought together key opinion leaders and regulatory and 
academia experts from Europe and beyond to discuss the role of 
modeling and simulation (M&S) in areas such as early medicine 
development, clinical pharmacology and dose-finding studies, special 
populations, optimization, and analysis of pivotal clinical trials.1 The 
fact that this meeting occurred indicates there is a meeting of minds 
on the role of modeling in drug development in particular, across a 
range of stakeholders. Perhaps modeling is coming in from the cold 
and is now being seen as part of the solution rather than as part of 
the problem.
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Summary: Corticosteroids are considered to be the mainstay of ther-
apy in noninfectious uveitis, until now, but side effects and complica-
tions related to such therapy, if systemically given, are well known. 
This is why in the recent period many local therapies have been 
proposed to treat noninfectious uveitis, especially intermediate and 
posterior. Corticosteroids can be given periocularly and intravitreally. 
Sub-Tenon injection (either via the orbital floor or transconjunctivally 
in the supero-temporal quadrant) with long-lasting steroids can be 
used every 15 to 60 days, and it is able to control uveitis as well 
as to treat macular edema. Apart from typical ocular side effects 
related to steroid therapy, such as cataract and intraocular pressure 
(IOP) increase, this way of administration can induce conjunctival 
and orbital floor fibrotic reaction, ptosis, retrobulbar hemorrhages, 
muscles paresis, optic nerve injury, and globe perforation. Intravitreal 
administration of steroids can be done either with a direct injection 
of triamcinolone, or with the placement into the vitreous cavity of a 
biodegradable dexamethasone implant (700 μ g, 4–6 months’ dura-
tion) or of a device able to deliver continuously for almost 3 years 
fluocinolone acetonide (0.59 mg). Their efficacy has been widely 
proven in treating noninfectious uveitis, but some local side effects 
(dexamethasone biodegradable implant: IOP increase in 25% of the 
patients; fluocinolone implant: cataract in 93% of the cases, IOP 
increase in 77%, 37% of whom requiring a surgical approach) 
could limit their use. In neither of the 2 aforementioned approaches 
is there a significant risk of developing endophthalmitis or retinal 
detachment. A questionable use of local therapy is in patients with 
an associated systemic disease and/or in those with bilateral uveitis. 
Nevertheless, in such a case, it is not rare to observe a very severe 
inflammatory ocular involvement with few systemic symptoms, 
and/or an asymmetric presentation of uveitis, which can be usefully 
comanaged with local, either periocular or intravitreal therapy.
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Summary: Abundant evidence from reviews of published research 
articles has demonstrated that a substantial proportion lack key 
information. A fundamental principle is that readers need to know 
exactly what was done and be given an accurate, complete and trans-
parent account of what was found. Readers should not be expected 
to take on trust that the authors have done a study without flaws. 
Furthermore, in principle, there should be enough detail to allow 
replication.
Widespread deficiencies in research publications weaken the 
evidence base for clinical practice. How can it be that none of the 
authors, peer reviews, or editors has detected that so many articles 
are substandard and, indeed, often unfit for purpose? Ensuring that 
journal articles are of maximum value to readers should be a priority 
for those who write research articles and those who review them. In 
recent years, many reporting guidelines have been developed, outlin-
ing the key elements of research that should be reported, with as-yet 
modest success. These and other related resources are available on 
the Web site of the EQUATOR Ne2rk. The best-known reporting 
guideline is the CONSORT Statement for reporting randomized tri-
als. Several extensions of CONSORT have been published. In this 
context, I will discuss the reporting of early clinical studies in phar-
macology.
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Summary: Major depression is a severe psychiatric syndrome with 
very high prevalence and socioeconomic impact. Its pathophysiology 
is poorly known, yet several neurotransmitter systems and brain areas 
have been implicated. Selective serotonin (5-hydroxytryptamine [5 
(-HT)]) reuptake inhibitors (SSRIs) and serotonin and norepinephrine 
reuptake inhibitors (SNRIs) are the most used antidepressant treat-
